Search
March 11, 2022

CDC-Abt Study Shows Pfizer Vaccine Is Moderately Effective for Children

Body

More than 300 news organizations, including CBS and Forbes, quoted Abt’s Lauren Olsho explaining the benefits of our PROTECT study for the CDC, which gathers and tests nasal swabs weekly from children, regardless of whether they had COVID-19 symptoms. “Without regular weekly testing you will miss many infections, particularly for kids, who often have mild symptoms,” said Olsho, the study’s principal investigator. Other pediatric vaccine studies captured only symptomatic cases, and with more home testing, studies like Abt’s are needed for a comprehensive view of vaccine effectiveness, she noted.

Read More

COVID-19 in North America

Abt at the Potomac Officers Club 2026 Healthcare Summit

Abt Global, Lead Platinum Sponsor of the POC 2026 Healthcare Summit, joins federal health leaders on AI, data, and access and hosts an AI governance panel.

Learn More
Event

New England Rural Health Association Conference 2026

Abt evaluator Julia Higgins presents RCORP findings for grantees based in rural New England at the NERHA 2026 Annual Conference, Nov. 18 in Concord, NH.

Learn More
Event

From Developers to Directors: Why the Agentic Era Requires a Post-Agile Delivery Model

The agentic era is changing who does the work. See how Abt’s Driftless methodology helps agencies modernize with human-led, agent-first software delivery.

Learn More
Blog

APPAM Fall Research Conference 2026

Abt is a Gold Sponsor of APPAM 2026. Catch us in Boston, in our sessions and at booth 304, or connect with the team here!

Learn More
Event